GENinCode Management

Management criteria checks 3/4

GENinCode's CEO is Matthew Walls, appointed in Sep 2018, has a tenure of 5.67 years. total yearly compensation is £352.54K, comprised of 81.1% salary and 18.9% bonuses, including company stock and options. directly owns 6.65% of the company’s shares, worth £867.48K. The average tenure of the management team and the board of directors is 5.7 years and 3.3 years respectively.

Key information

Matthew Walls

Chief executive officer

UK£352.5k

Total compensation

CEO salary percentage	81.1%
CEO tenure	5.7yrs
CEO ownership	6.6%
Management average tenure	5.7yrs
Board average tenure	3.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Matthew Walls's remuneration changed compared to GENinCode's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2023	n/a	n/a	-UK£7m
Mar 31 2023	n/a	n/a	-UK£6m
Dec 31 2022	UK£353k	UK£286k	-UK£6m
Sep 30 2022	n/a	n/a	-UK£6m
Jun 30 2022	n/a	n/a	-UK£5m
Mar 31 2022	n/a	n/a	-UK£5m
Dec 31 2021	UK£269k	UK£252k	-UK£4m
Sep 30 2021	n/a	n/a	-UK£3m
Jun 30 2021	n/a	n/a	-UK£2m
Mar 31 2021	n/a	n/a	-UK£1m
Dec 31 2020	UK£120k	n/a	-UK£1m
Dec 31 2019	UK£52k	n/a	-UK£303k

Compensation vs Market: Matthew's total compensation ($USD442.39K) is about average for companies of similar size in the UK market ($USD348.00K).

Compensation vs Earnings: Matthew's compensation has increased whilst the company is unprofitable.

CEO

Matthew Walls (59 yo)

5.7yrs

Tenure

UK£352,542

Compensation

Mr. Matthew Heaton Walls serves as Chief Executive Officer and Director of GENinCode Plc since September 6, 2018. He founded GENinCode in September 2018. He served as Executive Chairman of GENinCode Plc.H...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Matthew Walls	Co-Founder	5.7yrs	UK£352.54k	6.65% £ 867.5k
Jordi Puig Gilberte	Co-Founder	5.7yrs	UK£158.79k	8.25% £ 1.1m
Paul Andrew Foulger	CFO, Company Secretary & Director	3.5yrs	UK£158.05k	0.49% £ 64.0k

5.7yrs

Average Tenure

54yo

Average Age

Experienced Management: GENI's management team is seasoned and experienced (5.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Matthew Walls	Co-Founder	5.7yrs	UK£352.54k	6.65% £ 867.5k
Jordi Puig Gilberte	Co-Founder	5.7yrs	UK£158.79k	8.25% £ 1.1m
Paul Andrew Foulger	CFO, Company Secretary & Director	3.1yrs	UK£158.05k	0.49% £ 64.0k
William Rhodes	Independent Non-Executive Chairman	3.3yrs	UK£48.65k	no data
Felix Frueh	Independent Non-Executive Director	2.1yrs	UK£22.67k	0.057% £ 7.4k
Sergio Olivero	Independent Non-Executive Director	4yrs	no data	no data
Huon Gray	Independent Non-Executive Director	2.3yrs	UK£37.77k	0.28% £ 36.9k

3.3yrs

Average Tenure

59yo

Average Age

Experienced Board: GENI's board of directors are considered experienced (3.3 years average tenure).

GENinCode Management

Management criteria checks 3/4

Key information

Recent management updates

GENinCode Plc, Annual General Meeting, Jun 30, 2023

High number of new directors

GENinCode plc, Annual General Meeting, Jun 23, 2022

Less than half of directors are independent

Less than half of directors are independent

Genincode plc Announces the Appointment of Felix Frueh, as Non-Executive Director

Recent updates

New minor risk - Financial data availability

GENinCode Plc Announces Publication by the American Journal of Preventive Cardiology of A Study on 'Polygenic Risk and Incident Heart Disease in a Large Multiethnic Cohort

New major risk - Share price stability

GENinCode Plc has completed a Follow-on Equity Offering in the amount of £4.057378 million.

GENinCode plc Agrees with the Food and Drug Administration to Create New Regulatory Class for Polygenic Risk scores and Transition Its Premarket Notification 510(K) Submission to A De Novo Pathway

New major risk - Market cap size

First half 2023 earnings released: UK£0.037 loss per share (vs UK£0.024 loss in 1H 2022)

GENinCode Plc Provides Revenue Guidance for the Second Half of 2023

GENinCode Plc Provides Revenue Guidance for the Second Half of 2023

GENinCode Plc to Report First Half, 2023 Results on Sep 20, 2023

Genincode plc Announces CARDIO inCode study on risk of incident Coronary Heart Disease

GENinCode plc Files its Premarket Notification (510k) with the Food and Drug Administration to Expand Its US Commercial Distribution of the Cardio InCode-Score Polygenic Test for the Risk Assessment and Prevention of Coronary Heart Disease

New major risk - Financial position

GENinCode Plc, Annual General Meeting, Jun 30, 2023

Full year 2022 earnings: Revenues exceed analyst expectations

GENinCode Plc to Report Fiscal Year 2022 Results on Jun 06, 2023

Genincode plc Announces Approval of California State License and Clia Certification Opens Us Market

High number of new directors

First half 2022 earnings released: UK£0.027 loss per share (vs UK£0.088 loss in 1H 2021)

GENinCode plc, Annual General Meeting, Jun 23, 2022

Full year 2021 earnings: Revenues miss analyst expectations

GENinCode plc to Report Fiscal Year 2021 Results on May 17, 2022

Less than half of directors are independent

Less than half of directors are independent

Genincode plc Announces the Appointment of Felix Frueh, as Non-Executive Director

Genincode plc Appoints Huon Gray Cbe as an Independent Non-Executive Director

GENinCode plc Provides Positive Results for Lipid InCode in NHS Study

GENinCode Plc Announces FDA Pre-Submission for Cardio inCode-Score

Less than half of directors are independent

Independent Non-Executive Director David Evans has left the company

GENinCode plc (AIM:GENI) acquired Assets of Ferrer inCode and Gendiag.exe Businesses from Grupo Ferrer Internacional, S.A.

GENinCode Plc has completed an IPO in the amount of £17.000001 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age